Innovative Information System Optimizes Laboratory Processes
|
By LabMedica International staff writers Posted on 03 Aug 2016 |

Image: The new laboratory information system increases efficiency, streamlines workflow, reduces turnaround times, and promotes patient safety (Photo courtesy of CompuGroup Medical).
The CGM LABDAQ TELEIOS is a rules-based technology that supports compliance with best practices, medical necessity checking, and billing interfaces. Order routing rules automatically order reference lab versus in-house tests – based on patient insurance – to ensure reimbursement and minimize denials. Instrument data and quality control metrics are electronically captured and reviewed, and an advanced data-mining tool helps identify actionable insights needed to improve patient outcomes and make more informed business decisions.
Built on an Oracle database, CGM LABDAQ TELEIOS is Health Insurance Portability and Accountability Act (HIPAA)-compliant and includes a special quality module to simplify compliance and laboratory inspections. The system seamlessly integrates with a wide variety of electronic health record (EHR), billing systems, and reference lab interfaces, supporting meaningful use efforts and simplifying data exchange. Frequent updates and enhancements allow CGM LABDAQ TELEIOS to grow with customer needs. The CGM LABDAQ TELEIOS, a product of CompuGroup Medical (Phoenix, AZ USA), will be unveiled at AACC 2016.
“There is no better event in the laboratory space to truly show off CGM LADDAQ TELEIOS than at AACC, where we can demonstrate this powerful product to more than 20,000 laboratory scientists from around the world,” said Carl Smith, general manager of the CompuGroup Medical North America Lab Division. “The CGM LABDAQ team is excited about what this solution can do and the value it will bring to its users.”
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is an international scientific/medical society of over 8,000 clinical laboratory professionals, physicians, research scientists and more. The AACC annual meeting, which will be held from July 31st to August 4th at the Pennsylvania Convention Center in Philadelphia (USA), features five days of educational sessions on scientific, clinical, technical and management challenges facing laboratory professionals, as well as the world’s largest Clinical Lab Expo.
Related Links:
CompuGroup Medical
American Association for Clinical Chemistry
Built on an Oracle database, CGM LABDAQ TELEIOS is Health Insurance Portability and Accountability Act (HIPAA)-compliant and includes a special quality module to simplify compliance and laboratory inspections. The system seamlessly integrates with a wide variety of electronic health record (EHR), billing systems, and reference lab interfaces, supporting meaningful use efforts and simplifying data exchange. Frequent updates and enhancements allow CGM LABDAQ TELEIOS to grow with customer needs. The CGM LABDAQ TELEIOS, a product of CompuGroup Medical (Phoenix, AZ USA), will be unveiled at AACC 2016.
“There is no better event in the laboratory space to truly show off CGM LADDAQ TELEIOS than at AACC, where we can demonstrate this powerful product to more than 20,000 laboratory scientists from around the world,” said Carl Smith, general manager of the CompuGroup Medical North America Lab Division. “The CGM LABDAQ team is excited about what this solution can do and the value it will bring to its users.”
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is an international scientific/medical society of over 8,000 clinical laboratory professionals, physicians, research scientists and more. The AACC annual meeting, which will be held from July 31st to August 4th at the Pennsylvania Convention Center in Philadelphia (USA), features five days of educational sessions on scientific, clinical, technical and management challenges facing laboratory professionals, as well as the world’s largest Clinical Lab Expo.
Related Links:
CompuGroup Medical
American Association for Clinical Chemistry
Latest AACC 2016 News
- Molecular Test Detects Three Arboviruses in Plasma Samples
- Derived Exosomal Protein Biomarkers in Alzheimer’s Disease Diagnosis
- New Biochip Array Developed for ApoE4 Classification
- Cell-Free DNA Identifies Liver Transplant Patients with Acute Rejection
- New Method Tested for Early Diagnosis Pediatric Diabetic Nephropathy
- FDA-Cleared Automated Cell Counter for CSF Launched at AACC 2016
- Semen Analysis Portfolio with Two New Products Featured at AACC 2016
- Automation Solutions for Clinical Diagnostic Equipment Showcased at AACC 2016
- New Tubes Designed for Medium Sample Volumes
- Multi Sample Osmometer Improves Testing Efficiency
- Innovative eLearning Interface Seamlessly Connects Competency Data
- Cloud-Based Connectivity Platform Advances Decentralized Healthcare
- Adhesives Research to Present Hydrophilic Adhesive Technologies
- Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting
- Assay for Determination of 17-OH Progesterone to Be Featured at AACC Annual Meeting
- Fully Automated HbA1c Analyzer Available for Inspection at AACC Annual Meeting
Channels
Clinical Chemistry
view channel
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more
FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. Reference methods such as equilibrium dialysis with... Read moreMolecular Diagnostics
view channel
Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC
Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more
Realistic Mock Samples Aim to Speed Cervical Cancer Test Development
Cervical cancer remains highly preventable, yet screening access is limited in many low- and middle-income settings. Gold-standard tests for high-risk human papillomavirus (HPV) detect viral DNA or messenger... Read more
Molecular Marker Identifies Hormone Therapy Resistance Pathway in Prostate Cancer
Most prostate cancers depend on androgen signaling, making hormone suppression or blockade a central treatment strategy. Although many patients respond initially, tumors often adapt and eventually progress,... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more









